Cuiming Zhu

Prof. Cuiming Zhu

University of South China
+1

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
ZJZhulin Jiang
Zhulin Jiang
SLShuihong Li
Shuihong Li
CZCuiming Zhu
Cuiming Zhu
RZRunjie Zhou
Runjie Zhou
PLPolly Leung
Polly Leung
Mycoplasma pneumoniae is a major causative agent of community-acquired pneumonia which can lead to both acute upper and lower respiratory tract inflammation, and extrapulmonary syndromes. Refractory pneumonia caused by M. pneumonia can be life-threatening, especially in infants and the elderly. Here, based on a comprehensive review of the scientific literature related to the respective area, we summarize the virulence factors of M. pneumoniae and the major pathogenic mechanisms mediated by the pathogen: adhesion to host cells, direct cytotoxicity against host cells, inflammatory response-induced immune injury, and immune evasion. The increasing rate of macrolide-resistant strains and the harmful side effects of other sensitive antibiotics (e.g., respiratory quinolones and tetracyclines) in young children make it difficult to treat, and increase the health risk or re-infections. Hence, there is an urgent need for development of an effective vaccine to prevent M. pneumoniae infections in children. Various types of M. pneumoniae vaccines have been reported, including whole-cell vaccines (inactivated and live-attenuated vaccines), subunit vaccines (involving M. pneumoniae protein P1, protein P30, protein P116 and CARDS toxin) and DNA vaccines. This narrative review summarizes the key pathogenic mechanisms underlying M. pneumoniae infection and highlights the relevant vaccines that have been developed and their reported effectiveness.

30 April 2021 in Immunology
Verified
Journal Article
Open access
PDF file
YLYing Luo
Ying Luo
CLCheng Li
Cheng Li
ZZZhou Zhou
Zhou Zhou
ZGZhande Gong
Zhande Gong
CZCuiming Zhu
Cuiming Zhu
ALAihua Lei
Aihua Lei
Mycoplasmas are the smallest and simplest bacteria that lack a cell wall but have the capability of self‐replication. Among them, Mycoplasma pneumoniae is one of the most common causes of community‐acquired pneumonia. The hallmark of mycoplasma respiratory diseases is the persistence of lung inflammation that involves both innate and adaptive immune responses. In recent years, a growing body of evidence demonstrates that IL‐17 plays an important role in respiratory mycoplasma infection, and associates with the pathologic outcomes of infection, such as pneumonitis and asthma. Numerous studies have shown that a variety of cells, in particular Th17 cells, in the lung can secrete IL‐17 during respiratory mycoplasma infection. In this article, we review the biological functions of distinct IL‐17‐producing cells in mycoplasma respiratory infection with a focus on the effect of IL‐17 on the outcomes of infection.

18 April 2017 in Pathogens and Disease
Verified
Journal Article
Open access
PDF file
JHJihong Hu
Jihong Hu
CCChunyan Chen
Chunyan Chen
GOGuangli Ou
Guangli Ou
XYXiaoxing You
Xiaoxing You
TTTianping Tan
Tianping Tan
CZCuiming Zhu
Cuiming Zhu
A series of inflammatory responses caused by Mycoplasma pneumoniae largely depend on the lipid-associated membrane proteins (LAMPs). Nuclear factor E2-related factor 2 (Nrf2), a transcription factor, is considered to be a critical modulator of inflammatory responses and cellular redox homeostasis. Monocytes play an important role in the invasion and immunity to resist pathogens. Here, we investigated the role of Nrf2 in the anti-inflammatory response stimulated by LAMPs using the human monocyte cell line THP-1. LAMPs were shown to affect the localization of Nrf2, and the levels of reactive oxygen species and inflammatory reactants, including nitric oxide (NO), prostaglandin E2 (PGE2) and cytokines (IL-6, IL-8), were highly elevated in LAMP-stimulated Nrf2-silenced THP-1 cells. Moreover, LAMPs induced the levels of mRNA and the expression of heme oxygenase-1 (HO-1). In summary, our results demonstrated that LAMPs cause nuclear translocation of Nrf2, which further suppresses the expression of inflammatory reactants in THP-1 cells.


6 January 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
JHJiarong He
Jiarong He
WTWei Tian
Wei Tian
PFPengxiao Feng
Pengxiao Feng
TDTingfeng Du
Tingfeng Du
HLHuanbing Long
Huanbing Long
CZCuiming Zhu
Cuiming Zhu
Mycoplasma pneumoniae pneumonia (MPP) management presents significant challenges due to the lack of an effective vaccine and the widespread occurrence of macrolide resistance. Recent studies investigating the use of oral or intranasal probiotics have shown promising results in reducing respiratory tract infections. In this study, BALB/c mice were initially given intranasal doses of Lacticaseibacillus rhamnosus GG (LGG), Limosilactobacillus reuteri F275, or a combination of these two strains, called MIX, to evaluate the safety of probiotic administration by examining lung tissue inflammation. Our results suggest that LGG is relatively safe, with minimal lung inflammatory responses, unlike the mild inflammation seen with L. reuteri F275 and MIX treatments. Next, LGG was administered to the mice via the respiratory tract on two consecutive days before or after infection with M. pneumoniae . The findings showed that both pre- and post-infection intranasal LGG significantly reduced lung inflammation caused by M. pneumoniae and decreased the pathogen load. The protective effects of nasal LGG delivery were associated with an increase in alveolar macrophages, higher levels of IgA in the bronchoalveolar lavage fluid (BALF), and increased IgG levels in the serum, all of which contribute to the elimination of the pathogen. Additionally, LGG pretreatment decreased neutrophil levels in the BALF and lungs, suppressed pro-inflammatory cytokines (tumor necrosis factor α, interleukin [IL]-6, and IL-17A), and boosted the production of the anti-inflammatory cytokine IL-10 in the BALF, reducing MPP severity. Intranasal administration of LGG appears to be a safe and potentially effective strategy for alleviating MPP in mouse models. IMPORTANCE: The increasing prevalence of antibiotic-resistant Mycoplasma pneumoniae pneumonia (MPP), together with the absence of an effective vaccine, highlights the critical demand for alternative therapeutic approaches. This study demonstrates that intranasal delivery of Lacticaseibacillus rhamnosus GG (LGG) significantly mitigates pulmonary inflammation and decreases bacterial load in a mouse model of MPP, both prophylactically and therapeutically. Notably, LGG strengthens essential immune defenses by promoting alveolar macrophage recruitment, increasing secretory IgA in the airways, and stimulating systemic IgG. It also modulates cytokine production, suppressing pro-inflammatory mediators while enhancing anti-inflammatory IL-10. These findings support intranasal LGG administration as a strategy with promising translational potential for MPP.

6 October 2015
Verified
Journal Article
Closed access
GOG Ou
G Ou
YLY Liu
Y Liu
YTY Tang
Y Tang
XYX You
X You
YZY Zeng
Y Zeng
CZCuiming Zhu
Cuiming Zhu